Hit to Lead
We move your identified hits forward into in vivo testing and lead optimization
Our team is well-coordinated in providing a streamlined hit to lead transition while working closely with you on a meaningful and dedicated screening system to allow for efficient hit expansion. InnoSer provides robust and unbiased experimental design, methodology, analysis, interpretation, and reporting of results to support your journey into the Lead Optimization phase.
Our Approach
We support your needs with customized solutions
Our collaborative approach ensures that you see your hit compound’s properties improve to fulfill the necessary criteria moving into the Lead Optimization phase. Using multi-parametric methods we assess potency, selectivity, pharmacokinetic and physical properties enabling you to channel your resources into compounds that show promising signs of more uniform characteristics.
Partner with an Expert to Advance Your Therapeutic Discovery.
Work with our team to evaluate your drug and target for therapeutic effects with precision and expertise
Our Capabilities
We offer many of these studies, with increasing sample sizes, all the way from early research leading to informed and translatable late preclinical research.
We offer hit to lead development in a range of therapeutic fields and molecular entities using flexible and customizable hit to lead development steps. InnoSer provides functional assays, cell models, and in vivo methods to gain a robust overview of the strengths and optimization requirements of the investigational drug.
Our in-house expertise lies in immuno-oncology, cardio-metabolic, neurology, and nephrology. However, our established network of connections provides our clients with proactive, timely, and comprehensive services to reach therapeutic success in a range of therapeutic areas.
By providing a fully integrated solution, your project’s needs drive the services we provide and may feature one or more of the following services:
In vitro pharmacology
- General efficacy
- Cell migration assay
- Tumor invasion assay
- Chemotaxis
- Angiogenesis assay
- Cellular phosphorylation
- Cell cycle assay (FACS)
- Endocrine disruption
- Dose finding in in-vitro disease models
- IC50, EC50 and AUC
- Medium Throughput
In vitro ADME
- Solubility
- Permeability
- Hepatic Microsome Stability
- CYP450 Inhibition Profiling
- Plasma Stability
- Plasma Protein Binding
- Cytotoxicity
- Biocompatibility & Skin Sensitization
- Genotoxicity
- Nephrotoxicity
- Hepatotoxicity
Pharmacology
- Proof-of-Concept Studies
- Preliminary dose range finding (MTD)
Toxicology
- Single Dose Toxicity
- Repeated Dose Toxicity
- Toxicokinetics
Biocompatibility
Pharmacometrics
Navigate The Drug Development Pipeline
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com